Over 300 North Carolina Auctions End Tomorrow 08/10 - Bid Now
Over 2350 Total Lots Up For Auction at Three Locations - NJ 08/11, CA 08/12, TX 08/16

Three stages to COVID-19 brain damage identified by top neurologists in Journal of Alzheimer Disease paper

Press releases may be edited for formatting or style | June 12, 2020 Alzheimers/Neurology
NeuroCovid Stage III: An explosive level of cytokine storm damages the blood brain barrier, the protective insulation layer in blood vessels of the brain. As a result, blood content, inflammatory markers, and virus particles invade the brain and patients develop seizures, confusion, coma, or encephalopathy.
Fotuhi points out that many patients with COVID-19 may have no noticeable neurological symptoms at first; but in some cases, patients may present with neurological symptoms even before they have fever, cough, or shortness of breath. In addition to having an MRI while at the hospital, he stresses that patients will need to be monitored in a few months after their hospitalization.

"Our experience with previous forms of coronaviruses suggest that in the long-term patients may develop depression, insomnia, Parkinson's disease, memory loss, or accelerated aging in the brain," elaborated Fotuhi. "For those recovering from COVID-19, I recommend regular exercise, eating a heart healthy diet, reducing stress, and improving sleep; these are critical ways patients can rejuvenate their brain and minimize having poor outcomes in the future."

These interventions, along with targeted brain training and neurofeedback therapy, are the main features of Dr. Fotuhi's 12-week Brain Fitness Program. As published in the Journal of Prevention of Alzheimer's Disease (2016), 84% of elderly with cognitive impairment who complete this brain rehabilitation program gain improvements in their brain function and many of them experience growth in the parts of their brain for learning and memory. These findings were similar for patients who gained recovery from their persistent post-concussion syndrome. The program will now be tailored for patients suffering from post-COVID neurological issues.

A Harvard- and Johns Hopkins-trained neurologist and neuroscientist, Dr. Fotuhi is widely regarded as an authority in the field of memory, Alzheimer's Disease, concussion treatment, ADHD, and increasing brain vitality at any age.

Now in its 22nd year of publication, the Journal of Alzheimer's Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. The Journal of Alzheimer's Disease has a 2018 Journal Impact Factor of 3.517 according to Journal Citation Reports (Web of Science Group, 2019). JAD is published by IOS Press.

Back to HCB News

You Must Be Logged In To Post A Comment